World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 12 December 2020
Main ID:  NCT02889796
Date of registration: 31/08/2016
Prospective Registration: No
Primary sponsor: Gilead Sciences
Public title: Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate FINCH 1
Scientific title: A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks in Combination With Methotrexate to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Date of first enrolment: August 30, 2016
Target sample size: 1759
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT02889796
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).  
Phase:  Phase 3
Countries of recruitment
Argentina Australia Belgium Bulgaria Canada Czech Republic Czechia France
Germany Hong Kong Hungary India Ireland Israel Italy Japan
Korea, Republic of Mexico Netherlands New Zealand Poland Romania Russian Federation Serbia
Slovakia South Africa Spain Taiwan Thailand Ukraine United Kingdom United States
Contacts
Name:     Gilead Study Director
Address: 
Telephone:
Email:
Affiliation:  Gilead Sciences
Key inclusion & exclusion criteria

Key Inclusion Criteria:

- Have a diagnosis of RA (2010 ACR/EULAR criteria) , and are ACR functional class I-III.

- Have = 6 swollen joints (from a swollen joint count based on 66 joints (SJC66)) and =
6 tender joints (from a tender joint count based on 68 joints (TJC68)) at both
screening and Day 1.

- Ongoing treatment with a stable dose of MTX

Key Exclusion Criteria:

- Previous treatment with any janus kinase (JAK) inhibitor

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.



Age minimum: 18 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Rheumatoid Arthritis
Intervention(s)
Drug: Placebo to match filgotinib
Drug: Adalimumab
Drug: MTX
Drug: Filgotinib
Drug: Placebo to match adalimumab
Primary Outcome(s)
Proportion of Participants who Achieve an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12 [Time Frame: Week 12]
Secondary Outcome(s)
Change from Baseline in Clinical Disease Activity Index (CDAI) at Weeks 4, 12, 24, and 52, and Over Time from Day 1 through Week 52 [Time Frame: Baseline and up to 52 weeks]
Absolute Value and Change from Baseline in Short-form Health Survey (SF-36) at Weeks 4, 12, 24, and 52, and Over Time from Day 1 through Week 52 [Time Frame: Baseline and up to 52 weeks]
Proportion of Participants who Achieve ACR20 Over Time from Day 1 through Week 52 [Time Frame: Up to 52 weeks]
Absolute Value and Change from Baseline in the EuroQol 5 Dimensions (EQ-5D) Patient-Reported Outcomes Survey at Weeks 4, 12, 24, and 52, and Over Time from Day 1 through Week 52 [Time Frame: Baseline and up to 52 weeks]
Absolute Value and Change from Baseline in Work Productivity and Activity Impairment - Rheumatoid Arthritis (WPAI-RA) Patient-Reported Outcomes Survey at Weeks 4, 12, 24, and 52, and Over Time from Day 1 through Week 52 [Time Frame: Baseline and up to 52 weeks]
Change from Baseline in DAS28 (CRP) at Weeks 4, 12, 24, and 52, and Over Time from Day 1 through Week 52 [Time Frame: Baseline and up to 52 weeks]
Change from Baseline in Simplified Diagnostic Activity Index (SDAI) at Weeks 4, 12, 24, and 52, and Over Time from Day 1 through Week 24 [Time Frame: Baseline and up to 24 weeks]
Change from Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 12 [Time Frame: Week 12]
Proportion of Participants who Achieve ACR20 at Weeks 4, 24, and 52 [Time Frame: Weeks 4, 24, and 52]
Proportion of Participants who Achieve Disease Activity Score based on 28 joints (DAS28) (C-reactive protein (CRP)) = 3.2 at Week 12 [Time Frame: Week 12]
Change from Baseline in the mTSS at Week 52 [Time Frame: Baseline; Week 52]
Proportion of Participants who Achieve ACR 50% Improvement (ACR50) at Weeks 4, 12, 24, and 52 [Time Frame: Weeks 4, 12, 24, and 52]
European League Against Rheumatism (EULAR) Response at Weeks 4, 12, 24, and 52, and over time from Day 1 through Week 52 [Time Frame: Up to 52 weeks]
Proportion of Participants who Achieve DAS28 (CRP) < 2.6 at Weeks 4, 12, and 52, and over time from Day 1 through Week 52 [Time Frame: Up to 52 weeks]
American College of Rheumatology N (ACR-N) at Weeks 4, 12, 24, and 52, and over time from Day 1 through Week 52 [Time Frame: Up to 52 weeks]
Proportion of Participants who Achieve ACR 70% Improvement (ACR70) at Weeks 4, 12, 24, and 52 [Time Frame: Weeks 4, 12, 24, and 52]
Change from Baseline in the Modified Total Sharp Score (mTSS) at Week 24 [Time Frame: Week 24]
Proportion of Participants who Achieve ACR70 Over Time from Day 1 through Week 52 [Time Frame: Up to 52 weeks]
Absolute Value and Change from Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue) at Weeks 4, 12, 24, and 52, and Over Time from Day 1 through Week 52 [Time Frame: Baseline and up to 52 weeks]
Proportion of Participants who Achieve Change in HAQ-DI of = 0.22 at Weeks 4, 12, 24, and 52, and Over Time from Day 1 through Week 52 [Time Frame: Up to 52 weeks]
Proportion of Participants who Achieve DAS28 (CRP) = 3.2 at Weeks 4, 24, and 52, and Over Time from Day 1 through Week 52 [Time Frame: Up to 52 weeks]
Proportion of Participants with No Radiographic Progression from Baseline at Weeks 24 and 52 [Time Frame: Baseline; Weeks 24 and 52]
Proportion of Participants who Achieve DAS28 (CRP) < 2.6 at Week 24 [Time Frame: Week 24]
Change from Baseline in Individual Components of the ACR Response at Weeks 4, 12, 24, and 52 and Over Time from Day 1 through Week 52 [Time Frame: Baseline and up to 52 weeks]
Proportion of Participants who Achieve ACR50 Over Time from Day 1 through Week 52 [Time Frame: Up to 52 weeks]
Secondary ID(s)
2016-000568-41
GS-US-417-0301
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Galapagos NV
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history